Mirae Asset Global Investments
ARTV

Mirae Asset Global Investments’s Artiva Biotherapeutics ARTV Stock Holding History

Mirae Asset Global Investments’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-944
Closed -$2.71K – 1759
2025
Q3 		$2.71K Buy
944
+3
+0.3% +$8 ﹤0.01% 1627
2025
Q2 		$1.42K Buy
941
+128
+16% +$269 ﹤0.01% 1573
2025
Q1 		$2.57K Buy
813
+4
+0.5% +$22 ﹤0.01% 1534
2024
Q4 		$8.61K Buy
+809
New +$9.72K ﹤0.01% 1529

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mirae Asset Global Investments's ARTV Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 944 shares — an estimated $2.71K sold.

Mirae Asset Global Investments first reported a position in ARTV in Q4 2024 and held it in 4 quarters. The position peaked at $8.61K in Q4 2024. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • Mirae Asset Global Investments reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 944 Artiva Biotherapeutics shares in Q4 2025, an estimated $2.71K.
  • Mirae Asset Global Investments first reported a position in Artiva Biotherapeutics in Q4 2024 and held it in 4 quarters.
  • Mirae Asset Global Investments's Artiva Biotherapeutics position peaked at $8.61K in Q4 2024.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.